

Possible donor-dependent differences in efficacy of fresh frozen plasma for treatment of ACE inhibitor–induced angioedema

Sara X. Chen, MD^{a,b}, Daniela Hermelin, MD^c, and Steven J. Weintraub, MD^{a,b}



Clinical Implications

- Fresh frozen plasma has been used to treat angiotensin-converting enzyme inhibitor–induced angioedema, but outcomes have been variable. The data presented suggests that a component of the variability is due to differences in the angiotensin-converting enzyme activity content of fresh frozen plasma from different donors.

TO THE EDITOR:

Angiotensin-converting enzyme (ACE) inhibitors are among the most important and widely prescribed drugs. Unfortunately, their use carries the risk of causing upper airway angioedema that can progress to life-threatening respiratory compromise requiring intubation or a surgical airway. Deaths have occurred because of the difficulty in securing a patent airway in patients with angioedema and from complications of mechanical ventilation.

Attempts at developing a definitive treatment to reverse or at least block progression of ACE inhibitor–induced angioedema have been unsuccessful. Because bradykinin, an inflammatory mediator that is normally degraded by ACE, is elevated in patients with ACE inhibitor–induced angioedema,^{1,2} it had been thought that elevated levels of bradykinin underlie ACE inhibitor–induced angioedema. However, the bradykinin receptor antagonist icatibant was ineffective in the 2 largest randomized trials performed to date.^{3,4} Hence it has been proposed that other ACE-degraded inflammatory mediators, such as substance P^{1,2} and des-Arginine9-bradykinin,⁵ also contribute to ACE inhibitor–induced angioedema.

In this regard, it is notable that there are case reports and case series in which ACE replacement through transfusion of fresh frozen plasma (FFP) was effective in treating ACE inhibitor–induced angioedema.⁶ However, FFP is not uniformly effective and it has been reported that FFP can worsen ACE inhibitor–induced angioedema.⁷ One possible explanation for this variability that has not been considered in the literature is the potential variation in ACE activity levels between FFP units from different blood donors—indeed, it is likely that a number of donors take ACE inhibitors. Therefore, to begin to understand the variability in the efficacy of FFP, we assessed the circulating ACE activity levels among a typical group of Midwestern US blood donors.

ACE activity in serum samples from 330 blood donors in the American Red Cross Missouri/Illinois Blood Services Region was quantitated using the ACE kinetic test (Bühlmann Laboratories). Serum ACE activity levels correlate strongly with plasma ACE activity levels.⁸ The association between sex and ACE activity levels was assessed by the Mann-Whitney test. The association between




FIGURE 1. Frequency distribution histogram of ACE activity levels in blood donors.

age and ACE activity levels was assessed by Pearson correlation coefficient analyses. Analyses were performed using GraphPad Prism 8.0 (GraphPad Software, San Diego, Calif). The American Red Cross Institutional Review Board determined that this is not human studies research.

The frequency distribution of ACE activity levels among the donors (170 [51.5%] females; median age, 41 years, interquartile range, 25–58 years; range, 16–77 years; 310 white, 10 black, 4 Asian, 3 Hispanic, 1 Native-American, 2 Other) is shown in Figure 1 (median, 37.65 U/L; interquartile range, 27.1–48.8 U/L; range, <5–109.6 U/L). No association between sex and ACE activity level was detected ($P = .6446$). There was a weak inverse correlation between age and ACE activity level ($r = -0.1302$; $P = .0179$). Notably, 39 (11.8%) donors had ACE activity levels of 20 U/L or less, levels that are 95% specific for full compliance with ACE inhibitor use.⁹

These results demonstrate that there can be greater than a 20-fold difference in ACE activity levels between different units of FFP from an unselected group of blood donors. This strongly suggests that the variability in the reported efficacy of FFP for the treatment of ACE inhibitor–induced angioedema is at least in part due to a wide variation in ACE activity levels between different units of FFP. Furthermore, the results provide an explanation for how FFP transfusion could worsen an episode of angioedema or lengthen its time course (an effect that would not be recognized): FFP contains high molecular weight (HMW)-kininogen and kallikrein, the substrate and enzyme that generate bradykinin; therefore, transfusion of FFP with low ACE activity could increase a recipient's bradykinin levels.

The importance of developing an effective and safe treatment for ACE inhibitor–induced angioedema will further increase with the increasing use of ACE inhibitors as metabolic syndrome becomes more prevalent and the population ages. The ready availability and low cost of FFP make it an appealing potential therapy. Although several case reports and case series have suggested that FFP is efficacious, randomized controlled trials to prove its benefit are imperative. Our findings indicate that these trials should use FFP that contains high levels of ACE activity.

Acknowledgments

We thank Judy Grishaber, DO, Medical Director of the American Red Cross Missouri/Illinois Blood Services Region, for assistance with obtaining institutional review board review, coordinating the transfer of the serum samples, and critical review of the manuscript. We thank David Gibson for his expert technical assistance.

^aDivision of Hospital Medicine, Department of Medicine, Saint Louis Veterans Affairs Medical Center, Saint Louis, Mo

^bDepartment of Medicine, Washington University School of Medicine, Saint Louis, Mo

^cDepartment of Pathology, Saint Louis University School of Medicine, Saint Louis, Mo
This study was supported by the Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication December 27, 2018; revised February 7, 2019; accepted for publication February 8, 2019.

Available online March 2, 2019.

Corresponding author: Steven J. Weintraub, MD, Division of Hospital Medicine, Department of Medicine, St Louis VA Medical Center, 915 North Grand Ave, St Louis, MO 63106. E-mail: sjweintraub@gmail.com.

2213-2198

Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

<https://doi.org/10.1016/j.jaip.2019.02.027>

REFERENCES

1. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. *Lancet* 1998;351:1693-7.
2. Hubers SA, Kohm K, Wei S, Yu C, Nian H, Grabert R, et al. Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema. *J Allergy Clin Immunol* 2018;142:1636-1639.e5.
3. Straka BT, Ramirez CE, Byrd JB, Stone E, Woodard-Grice A, Nian H, et al. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. *J Allergy Clin Immunol* 2017;140:242.
4. Sinert R, Levy P, Bernstein JA, Body R, Sivilotti MLA, Moellman J, et al. Randomized trial of icatibant for angiotensin-converting enzyme inhibitor-induced upper airway angioedema. *J Allergy Clin Immunol Pract* 2017;5:1402-3.
5. Molinaro G, Cugno M, Perez M, Lepage Y, Gervais N, Agostoni A, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. *J Pharmacol Exp Ther* 2002;303:232-7.
6. Riha HM, Summers BB, Rivera JV, Van Berkel MA. Novel therapies for angiotensin-converting enzyme inhibitor-induced angioedema: a systematic review of current evidence. *J Emerg Med* 2017;53:662-79.
7. Adebayo O, Wilkerson RG. Angiotensin-converting enzyme inhibitor-induced angioedema worsened with fresh frozen plasma. *Am J Emerg Med* 2017;35:192.e1-2.
8. Anguiano L, Riera M, Pascual J, Valdivielso JM, Barrios C, Betriu A, et al. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. *Nephrol Dial Transplant* 2015;30:1176-85.
9. Struthers AD, MacFadyen R, Fraser C, Robson J, Morton JJ, Junot C, et al. Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure. *J Am Coll Cardiol* 1999;34:2072-7.

Reproduced with permission of copyright owner. Further reproduction prohibited without permission.